Search hospitals
>
Manitoba
>
WINNIPEG
CancerCare Manitoba
Claim this profile
WINNIPEG, Manitoba R3E 0V9
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Brain Tumor
Conducts research for Leukemia
Conducts research for Lymphoma
433 reported clinical trials
19 medical researchers
Summary
CancerCare Manitoba is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Cancer, Breast Cancer, Brain Tumor, Leukemia, Lymphoma and other specialties. CancerCare Manitoba is involved with conducting 433 clinical trials across 439 conditions. There are 19 research doctors associated with this hospital, such as Ashley Chopek, Issai M. Vanan, Versha Banerji, and Kristjan Paulson.
Area of expertise
Cancer
CancerCare Manitoba has run 46 trials for Cancer. Some of their research focus areas include:
Breast Cancer
CancerCare Manitoba has run 42 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Ashley Chopek
CancerCare Manitoba
6 years of reported clinical research
Issai M. Vanan
CancerCare Manitoba
6 years of reported clinical research
Versha Banerji
Cancer Care Manitoba
3 years of reported clinical research
Kristjan Paulson
CancerCare Manitoba
7 years of reported clinical research
Clinical Trials running at CancerCare Manitoba
Cancer
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Testicular cancer
Acute Myelogenous Leukemia
Wilms Tumor
Myelodysplastic Syndrome
Breast Cancer
Neuroblastoma
Lymphoma
Triptorelin
for Cancer
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Recruiting
2 awards
Phase 3
4 criteria
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting
2 awards
Phase 3
26 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at CancerCare Manitoba?
CancerCare Manitoba is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Cancer, Breast Cancer, Brain Tumor, Leukemia, Lymphoma and other specialties. CancerCare Manitoba is involved with conducting 433 clinical trials across 439 conditions. There are 19 research doctors associated with this hospital, such as Ashley Chopek, Issai M. Vanan, Versha Banerji, and Kristjan Paulson.
Where is CancerCare Manitoba located?
CancerCare Manitoba is situated at 675 McDermot Avenue, Winnipeg, MB, near the intersection of McDermot Avenue and William Avenue.
Who should I call to ask about financial aid or insurance network?
**CancerCare Manitoba Financial Assistance and Insurance Inquiries:** - For financial assistance, contact the CancerCare Co-Payment Assistance Foundation at 800-813-HOPE (4673). They provide support for transportation, home care, child care, and pet assistance for those with a confirmed cancer diagnosis, undergoing active treatment, residing in the U.S. or Puerto Rico, and meeting Federal Poverty Limit guidelines. - CancerCare's "Managing the Cost of Cancer" booklet and the Purpose in Planning Coping Circle Series - Part I workshop offer resources and tips for managing cancer care costs and financial planning. - In Manitoba, the Canadian Cancer Society's Access to Care program offers treatment-related travel and accommodation assistance for eligible individuals. CancerCare Manitoba provides free counseling on Manitoba’s Insured Health Benefits. - The Government of Canada supports cancer patients through Employment Insurance (EI), sickness benefits, caregiving benefits, tax deductions, and the Canada Pension Plan (CPP).
What insurance does CancerCare Manitoba accept?
CancerCare Manitoba is a provincially mandated cancer agency offering clinical services to both children and adults, covered under Manitoba Health for Manitoba residents. This coverage includes physicians' services, surgery, anaesthesia, x-ray, and laboratory services in approved facilities. For out-of-province and out-of-country care, Manitoba Health provides certain coverages, but additional health insurance is recommended to cover excluded services and potential extra charges.
What awards or recognition has CancerCare Manitoba received?
CancerCare Manitoba Hospital, located in Winnipeg, Manitoba, benefits from substantial funding provided by the CancerCare Manitoba Foundation, thanks to the generous support of Manitobans. This financial backing has facilitated the hospital in leading and participating in clinical trials, funding local cancer research, and enhancing care and services for patients. The hospital's Research Institute, supported by over 40 scientists, concentrates on a broad spectrum of inquiries related to cancer and blood disorders.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.